desk
Share
News Topical, Digital Desk : Pharma company Jagsonpal Pharmaceuticals Limited has made a major decision for its shareholders. The company's board has approved a share buyback proposal. This decision was made at the board meeting held on March 12, 2026. According to the company, it will buy back a maximum of 1,600,000 equity shares. This represents approximately 2.39% of the company's total paid-up capital.
Under the buyback, the company will purchase shares at a price of ₹250 per share. The total size of the plan will be up to ₹40 crore. This amount represents approximately 18.35% of the company's paid-up capital and free reserves, as per its audited financial position as of March 31, 2025. The company stated that the buyback will be completed on a proportionate basis through the tender offer route, in accordance with SEBI buyback regulations.
Who will be the manager?
Centrum Capital Limited has been appointed as the manager for this buyback. The company has also formed a buyback committee, which will make decisions related to setting the record date and the entire process.
The company has clarified that the promoter and promoter group will not participate in this buyback. A separate postal ballot process will be initiated to obtain shareholder approval.
According to the pre- and post-buyback shareholding pattern detailed in the document, the promoter group's stake could increase from approximately 67.2% to 68.9% after the buyback, while public shareholding could decrease from 32.8% to approximately 31.1% if the full buyback is completed.
According to experts, share buybacks reduce the number of shares available in the market, which could help enhance shareholder value.
--Advertisement--
